マイラン製薬（株）

What マイラン製薬（株） does

Viatris Japan, operated through ヴィアトリス・コーポレーション合同会社 (Viatris Corporation G.K.), is the Japanese subsidiary of Viatris Inc., a global pharmaceutical company formed in November 2020 through the merger of Mylan N.V. and Pfizer's off-patent medicines division Upjohn. The Japanese entity is headquartered in Minato-ku, Tokyo, and markets a broad pharmaceutical portfolio organized into three core product categories: therapeutic-area products (covering both non-communicable and infectious diseases), product information resources (for prescription drugs and OTC medicines), and disease information content for healthcare professionals and patients across all life stages.

The parent company, Viatris Inc. (NASDAQ: VTRS), operates a global manufacturing and distribution platform spanning 165+ countries and regions, supported by 26 manufacturing sites with annual production capacity exceeding 80 billion tablets and capsules, and 60+ global partner organizations. The combined entity's value proposition rests on economies of scale in off-patent and generic pharmaceutical production, regulatory compliance evidenced by 135+ annual health authority inspections, and a broad therapeutic-area distribution network. The product line is unified under the Viatris brand, with the Mylan Inc. and Upjohn names retained as wholly-owned subsidiary brands.

Revenue mechanics follow the standard off-patent and generics pharmaceutical model: manufacturing and selling established-molecule drugs across multiple therapeutic categories, with pricing negotiated through national health systems, hospital networks, and pharmacy wholesalers. In Japan, the local G.K. subsidiary focuses on product registration, regulatory liaison with the PMDA, marketing, and distribution rather than domestic manufacturing; the Japanese entity operates with a small local headcount of 10 employees per the input data. Go-to-market channels include a corporate website (viatris.jp), Japanese and global press releases, social media (LinkedIn, Instagram, X/Twitter, YouTube), and a dedicated Japan recruitment site (recruit-japan.viatris.jp).

Name

マイラン製薬（株）

Legal name

Viatris Inc.

Website

https://mylan.co.jp

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Viatris Japan (ヴィアトリス・コーポレーション合同会社) is the Japanese subsidiary of Viatris Inc. (NASDAQ: VTRS), a global off-patent pharmaceutical company operating in 165+ countries with 26 manufacturing sites producing 80 billion+ tablets annually. It markets generic and branded pharmaceutical products across non-communicable and infectious disease therapeutic areas to Japan's healthcare system and professionals.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Marketing channels4 records

Core offering

マイラン製薬（株） (Viatris Japan) is a pharmaceutical company that manufactures and distributes a broad portfolio of high-quality medicines across multiple therapeutic areas, covering non-communicable diseases and infectious diseases for all life stages. The company operates within Viatris Inc.'s global infrastructure of 26 manufacturing sites producing over 80 billion tablets and capsules annually, serving 165+ countries and regions. As a subsidiary of the publicly listed Viatris Inc. (NASDAQ: VTRS), the Japanese entity focuses on supplying pharmaceuticals to healthcare systems, hospitals, and pharmacies in Japan.

Product overview

ヴィアトリスは製薬会社として、統一された製品ポートフォリオを持っています。製造拠点26カ所、年間800億錠以上の生産能力を有し、165カ国・地域以上で事業展開。製品ラインアップは、非感染性疾患および感染症の両方に対応する高品質な医薬品で構成されており、「製品情報」「治療領域別」「疾患情報」の各セクションを通じて提供されています。

Differentiator

Problem solved

Functional benefit

Brands

• Viatris: Global healthcare company brand offering pharmaceuticals across multiple therapeutic areas including non-communicable diseases and infectious diseases.

Products and services

• Pharmaceutical products by therapeutic area (製薬製品（治療領域別）) A broad portfolio of high-quality pharmaceutical products spanning multiple therapeutic areas, from non-communicable diseases (such as cardiovascular, respiratory, diabetes, oncology) to infectious diseases, designed for patients across all life stages. Supplied to healthcare systems, hospitals, and pharmacies through the Viatris global distribution network.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Cipla: Major Indian off-patent pharmaceutical manufacturer with leading positions in respiratory, antiretroviral, and chronic therapy areas; comparable to Viatris in serving high-volume, cost-sensitive global healthcare markets.
• Sandoz Group: Spun off from Novartis in 2023 as a focused generics and biosimilars business, Sandoz competes head-to-head with Viatris in off-patent small molecules and biosimilars across global markets, sharing a similar diversified geographic and therapeutic footprint.
• Sun Pharmaceutical Industries: India's largest specialty generics manufacturer with global commercial reach including the US, emerging markets, and Japan-adjacent APAC — comparable to Viatris as a broad-line, off-patent-focused pharmaceutical manufacturer with strong cost position.
• Aurobindo Pharma: Vertically integrated Indian generic manufacturer with one of the largest US generic footprints and growing presence in EU and emerging markets; competes with Viatris in oral solids, injectables, and increasingly complex generics.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, with a broad off-patent portfolio, global manufacturing, and a strong footprint across both developed and emerging markets — directly comparable to Viatris across product category, customer base, and business model.
• Dr. Reddy's Laboratories: India-based generics and biosimilars company with significant US and emerging-market revenue, overlapping with Viatris on therapeutic breadth, manufacturing scale, and customer base (pharmacies, hospitals, governments).
• Lupin Pharmaceuticals: India-based generics company with strong US franchise in oral contraceptives, cardiovascular, and CNS; competes with Viatris on global off-patent manufacturing scale and therapeutic breadth.

Broad incumbents

• Pfizer: Former parent of the Upjohn division that merged with Mylan to form Viatris; as a broad incumbent, Pfizer retains significant overlap in off-patent products and global commercial reach, even though its strategic focus has shifted to innovative therapies and biologics.

Regional players

• Sawai Group Holdings: Largest Japanese generics manufacturer by domestic sales, competing with Viatris Japan in the same Japanese off-patent market with similar product categories (chronic disease, cardiovascular, CNS), but operating primarily within Japan.
• Nichi-Iko Pharmaceutical: Major Japan-focused generics company with broad domestic distribution and biosimilar ambitions; overlaps with Viatris Japan on therapeutic categories and Japanese customer base but does not directly compete in global off-patent markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/viatrisinc
• YouTubeyoutube.com/channel/UCWVqREHI9o39CMlIzqczAag
• LinkedInlinkedin.com/company/%E3%83%9E%E3%82%A4%E3%83%A9%E3%83%B3%E8%A3%BD%E8%96%AC%EF%BC%88%E6%A0%AA%EF%BC%89
• Instagraminstagram.com/viatrisinc

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about マイラン製薬（株）